Dishman Carbogen — 360° view

Dishman Carbogen, a company in the Pharmaceuticals industry, reported revenue of ₹507 crore and a net loss of ₹67 crore for the September 2026 quarter.

Dishman Carbogen (NSE: DCAL) closed at ₹115.57 on 20 Nov 2026, down 53.0% over the past year. Its market capitalisation is ₹1,812 crore.

Share price
₹115.57 (20 Nov 2026)
Market cap
₹1,812 Cr (20 Nov 2026)
Revenue
₹507 Cr (September 2026 quarter)
Net profit
₹-67 Cr (September 2026 quarter)
ROCE
3.14% (FY26)
ROE
1.58% (FY26)
Book value
₹426 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹274.30 / ₹115.00 (20 Nov 2026)
1-year return
-53.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: DCAL

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.